Morgan Stanley lifts CVS Health Corporation [CVS] price estimate. Who else is bullish?

CVS Health Corporation [NYSE: CVS] stock went on an upward path that rose over 0.47% on Tuesday, amounting to a one-week price increase of more than 3.05%. The company report on November 25, 2022 that CIBC Launches 5 New CDRs (“Canadian Depositary Receipts”) on the NEO Exchange.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Expanded CDR lineup makes global investing easier than ever for Canadian investors – 35 CDRs now available.

NEO is proud to welcome CIBC back to the NEO Exchange with a suite of five new Canadian Depositary Receipts (“CDRs”) to expand their existing lineup to 35 global companies.

Over the last 12 months, CVS stock rose by 9.63%. The one-year CVS Health Corporation stock forecast points to a potential upside of 14.37. The average equity rating for CVS stock is currently 2.20, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $131.82 billion, with 1.31 billion shares outstanding and 1.31 billion shares in the current float. Compared to the average trading volume of 5.94M shares, CVS stock reached a trading volume of 3427460 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on CVS Health Corporation [CVS]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CVS shares is $117.81 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CVS stock is a recommendation set at 2.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for CVS Health Corporation shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 23, 2022. While these analysts kept the previous recommendation, Loop Capital raised their target price to Buy. The new note on the price target was released on June 17, 2022, representing the official price target for CVS Health Corporation stock. Previously, the target price had yet another drop from $122 to $112, while Bernstein kept a Mkt Perform rating on CVS stock.

The Average True Range (ATR) for CVS Health Corporation is set at 2.16, with the Price to Sales ratio for CVS stock in the period of the last 12 months amounting to 0.42. The Price to Book ratio for the last quarter was 1.88, with the Price to Cash per share for the same quarter was set at 15.30. Price to Free Cash Flow for CVS in the course of the last twelve months was 7.92 with Quick ratio for the last quarter at 0.70.

CVS Stock Performance Analysis:

CVS Health Corporation [CVS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.05. With this latest performance, CVS shares gained by 7.10% in over the last four-week period, additionally plugging by 4.27% over the last 6 months – not to mention a rise of 9.63% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CVS stock in for the last two-week period is set at 60.26, with the RSI for the last a single of trading hit 63.48, and the three-weeks RSI is set at 57.61 for CVS Health Corporation [CVS]. The present Moving Average for the last 50 days of trading for this stock 96.12, while it was recorded at 100.42 for the last single week of trading, and 98.79 for the last 200 days.

Insight into CVS Health Corporation Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and CVS Health Corporation [CVS] shares currently have an operating margin of +5.12 and a Gross Margin at +17.77. CVS Health Corporation’s Net Margin is presently recorded at +2.71.

Return on Equity for this stock inclined to 10.95, with Return on Assets sitting at 3.30.

CVS Health Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.70 and a Current Ratio set at 0.90.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CVS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for CVS Health Corporation go to 5.47%.

CVS Health Corporation [CVS] Insider Position Details

There are presently around $104,742 million, or 80.60% of CVS stock, in the hands of institutional investors. The top three institutional holders of CVS stocks are: VANGUARD GROUP INC with ownership of 115,934,841, which is approximately 1.512% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 93,850,627 shares of the stock with an approximate value of $9.47 billion in CVS stocks shares; and CAPITAL WORLD INVESTORS, currently with $6.14 billion in CVS stock with ownership of nearly 3.502% of the company’s market capitalization.

Positions in CVS Health Corporation stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 1,164 institutional holders increased their position in CVS Health Corporation [NYSE:CVS] by around 35,706,880 shares. Additionally, 1,034 investors decreased positions by around 29,629,087 shares, while 241 investors held positions by with 972,944,812 shares. The mentioned changes placed institutional holdings at 1,038,280,779 shares, according to the latest SEC report filing. CVS stock had 140 new institutional investments in for a total of 3,204,351 shares, while 97 institutional investors sold positions of 2,524,279 shares during the same period.


Please enter your comment!
Please enter your name here